Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito strategy.
All StrategiesRecent trades of NVS by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: Anti-cdh6 antibody drug conjugates May. 29, 2018
-
Patent Title: Synthetic apelin mimetics for the treatment of heart failure May. 29, 2018
-
Patent Title: Heteroaryl butanoic acid derivatives May. 29, 2018
-
Patent Title: Reusable lens molds and methods of use thereof May. 29, 2018
-
Patent Title: Reusable lens molds and methods of use thereof May. 29, 2018
-
Patent Title: Dual mode vitrectomy surgical system May. 22, 2018
-
Patent Title: Administration of bimagrumab for improving muscle mass and function after hip fracture surgery May. 15, 2018
-
Patent Title: Ophthalmic lens having an extended depth of focus May. 15, 2018
-
Patent Title: Ophthalmic illumination systems, devices, and methods May. 15, 2018
-
Patent Title: Surgical guidance and planning software for astigmatism treatment May. 15, 2018
-
Patent Title: Compounds and compositions for the treatment of parasitic disease May. 08, 2018
-
Patent Title: Ophthalmic device having therapeutic agent delivery capability and method of forming same May. 08, 2018
-
Patent Title: Active acoustic streaming in hand piece for occlusion surge mitigation May. 08, 2018
-
Patent Title: Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators May. 01, 2018
-
Patent Title: Cannula with an integrated illumination feature May. 01, 2018
-
Patent Title: Method and system to detect ophthalmic tissue structure and pathologies May. 01, 2018
-
Patent Title: Method for determining the surface concentration of carboxyl groups on a lens Apr. 24, 2018
-
Patent Title: Use of inhibitors of the activity or function of pi3k Apr. 24, 2018
-
Patent Title: Apparatus for monitoring one or more surgical parameters of the eye Apr. 24, 2018
-
Patent Title: Notch2 binding molecules for treating respiratory diseases Apr. 17, 2018
-
Patent Title: Compounds and compositions as toll-like receptor 7 agonists Apr. 17, 2018
-
Patent Title: Lens holder for contact vitrectomy lens Apr. 17, 2018
-
Patent Title: Brake system Apr. 10, 2018
-
Patent Title: Nucleic acid encoding anti-il-17a antibodies Apr. 10, 2018
-
Patent Title: Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase Apr. 10, 2018
-
Patent Title: N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 Apr. 10, 2018
-
Patent Title: Inhibitors for treating diseases characterized by atrial enlargement or remodeling Apr. 10, 2018
-
Patent Title: Adjusting laser treatment in response to changes in the eye Apr. 10, 2018
-
Patent Title: Powered case for electro-active medical device battery management Apr. 03, 2018
-
Patent Title: Quick-opening vent valve for phaco fluidics aspiration system Apr. 03, 2018
-
Patent Title: Synthetic apelin fatty acid conjugates with improved half-life Apr. 03, 2018
-
Patent Title: Carboxamide derivatives Apr. 03, 2018
-
Patent Title: Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders Apr. 03, 2018
-
Patent Title: Dual optic, curvature changing accommodative iol having a fixed disaccommodated refractive state Apr. 03, 2018
-
Patent Title: Edge design for reducing unwanted photic effects in intraocular lenses Apr. 03, 2018
-
Patent Title: Fast and automated segmentation of layered image with heuristic graph search Mar. 27, 2018
-
Patent Title: Compounds and compositions for the treatment of parasitic diseases Mar. 27, 2018
-
Patent Title: Vitrectomy probe with integral valve Mar. 27, 2018
-
Patent Title: Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor Mar. 20, 2018
-
Patent Title: Low-water content acrylate-acrylamide copolymers for ophthalmic devices Mar. 20, 2018
-
Patent Title: Water-processable silicone-containing prepolymers and uses thereof Mar. 20, 2018
-
Patent Title: Method for producing ophthalmic lenses Mar. 20, 2018
-
Patent Title: Aspheric optical lenses and associated systems and methods Mar. 20, 2018
-
Patent Title: Acoustic pumps and systems Mar. 13, 2018
-
Patent Title: Method of separating excess lens forming material from a molded ophthalmic lens, in particular a contact lens Mar. 13, 2018
-
Patent Title: Combination of a pi3 kinase inhibitor with pacitaxel for use in the treatment or prevention of a cancer of the head and neck Mar. 13, 2018
-
Patent Title: Combination therapy Mar. 13, 2018
-
Patent Title: Benzothiazolone compound Mar. 13, 2018
-
Patent Title: Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof Mar. 06, 2018
-
Patent Title: Antibody molecules to lag-3 and uses thereof Mar. 06, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
We estimate that -- received a compensation of -- in --, making them the highest paid executive at NVS, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|